Background. Little information is available regarding the mechanisms involved in cytokine-induced type 1 inositol 1,4,5-trisphosphate receptor (IP 3 R1) expression in human mesangial cells (HMCs) in the occurrence of hepatorenal syndrome (HRS). Over-expression of IP 3 R1 would enhance both IP 3 -binding activity and sensitivity. We hypothesize that it is possible that increased IP 3 R1, induced by TNFα, would lead to increased IP 3 sensitivity in response to a variety of vasoconstrictors, and promote HMC contraction and thus lead to reduced GFP, promoting HRS occurrence and development. Methods. Quantitative real-time polymerase chain reaction and immunoblot assay were used to examine the effects of TNFα on IP 3 R1 mRNA and protein expression. Several inhibitors of kinases, depletion PKC, over-expression of dominant-negative mutant of PKC and non-radioactive PKC assay were used to examine the mechanism of signal transduction of TNFα-regulated IP 3 R1 in HMCs. Results. TNFα increased IP 3 R1 mRNA and protein expression in HMCs, an effect that was blocked by prolonged incubated chronic PMA, D609, safingol and also by transfection with domain-negative PKCα construct. TNFα activated and promoted autophosphorylation of the PKCα. In addition, both anti-TNFR1 and anti-TNFR2 antibodies blocked TNFα-induced IP 3 R1 protein expression, while only anti-TNFR1 antibodies but not anti-TNFR2 antibodies attenuated TNFα-induced PKCα activity. Conclusions. TNFα increased the expression of IP 3 R1, and this was mediated, at least in part, through the TNFR1/PC-PLC/PKCα and TNFR2 signalling pathways in HMCs.
Introduction
Hepatorenal syndrome (HRS) is a frequent complication in patients with advanced cirrhosis and severe liver injury. The hallmark of HRS is renal vasoconstriction [1] . An accumulating body of evidence suggests that the serum level of TNFα increases significantly in patients with severe liver injury [2, 3] , and it has been demonstrated that the TNFα inhibitor, oxpentifylline, reduced the incidence of HRS from 35% to 8% [4] .
The inositol 1,4,5-trisphosphate receptor (IP 3 R) is an intracellular calcium ion (Ca 2+ ) channel that triggers the release of Ca 2+ from internal Ca 2+ stores in response to inositol 1,4,5-trisphosphate (IP 3 ). Cell contraction is closely connected with changes in intracellular Ca 2+ concentration. IP 3 R1, one subtype of IP 3 R, is predominant in the GMCs and renal VSMC [5] . Glomerular mesangial cells (GMCs) modify GFP via alternations in glomerular capillary filtration surface area due to the ability of contract [6] . The level of IP 3 R1 expression can be altered by many factors [7] [8] [9] [10] . Over-expression of IP 3 R1 would enhance both IP 3 -binding activity and sensitivity, and Ca 2+ -releasing activity [11] . For example, elevated IP 3 R1 might be causally related to initiating or perpetuating diseases such as atrial fibrillation and asthma [12, 13] ; IP 3 R1 up-regulated by TNFα correlated with alterations in Ca 2+ homeostasis and might be associated with Parkinson's disease [14] . Wen et al. discovered that the elevated IP 3 R1 in the kidneys of mice with fulminant hepatic failure would be responsible for renal hypofiltration and GFP reduction [15] . In contrast, reduction in IP 3 R1 expression induced by transforming growth factor-β might lead to diminished vascular responsiveness of GMCs and smooth muscle cells [16] .
Therefore, we hypothesis that it is possible that increased IP 3 R1, induced by TNFα, would lead to increased IP 3 sensitivity and Ca 2+ -releasing activity in response to a variety of vasoconstrictors when HRS occurred, promoting GMCs and renal VSMC contraction, GFP reduction, and HRS occurrence and development. Therefore, we examine our hypothesis whether TNFα affected IP 3 R1 expression in HMCs, and if so, what kind of mechanisms are involved in TNFα-induced IP 3 R1 expression. It is essential to understand this mechanism of the action of TNFα in the exacerbation of renal ischaemic injury in order to identify target molecules that could modulate the pathogenesis of HRS.
Materials and methods

Materials
TNFα, anti-TNFR1 and anti-TNFR2 were obtained from R&D System (Minneapolis, MN, USA); phorbol-12-myristate 13-acetate (PMA), pp1, rottlerin, U73122 and D609 were from Calbiochen (Schwalbach, Germany); safingol and anti-HA-tag mAb (12CA5) were from Sigma (Aldrich, St. Louis, MO, USA). Anti-IP 3 R1 and anti-β-actin were from Chemicon International. Anti-pan PKC, anti-PKCα and anti-p-PKCα [phosphorylated PKCα at residue 638 (threonine)] were from Cell Signaling Technology (Frankfurt am Main, Germany). The goat HRP-conjugated anti-rat IgG1 was from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Well-characterized plasmid constructs for the expression of dominantnegative mutant PKCα (pHACE-DN-PKCα), wild-type PKCα (pHACE-WT-PKCα) and pcDNA3.0 plasmids were generous gifts from Dr Jae-Won Soh (University of Inha, Inha, Republic of Korea [17] ). The PepTag nonradioactive protein kinase C (PKC) assay system was from Promega (Madison, WI, USA). The Trizol reagent was from Invitrogen. The transfection agents, Oligofectamine and Lipofectamine 2000, were from Invitrogen.
Cell culture and chemical treatments of HMCs
Primary culturing HMCs and mesangial cell medium (MCM 4201) were from the Science Cell Research Laboratories (San Diego, CA, USA). HMCs were plated onto (2 mL/well) six-well culture plates and (10 mL/dish) 10-cm culture dishes for the measurement of mRNA accumulation and protein expression, respectively. Experiments were performed with cells from passages 3-8.
Experiments were firstly performed to determine the effects of TNFα on IP 3 R1 gene and protein expression. HMCs were grown in MCM containing 2% FCS until reaching 90% confluency, followed by MCM without FCS for 24 h before TNFα stimulation for 2-24 h. Then, total RNA or protein extraction at various time points was harvested for quantitative real-time polymerase chain reaction (qRT-PCR) and western blot analysis.
Further experiments were conducted for the regulatory role of PLC, PKC and PP1 on TNFα-stimulated IP 3 R1 expression by incubating cells with selective protein kinase inhibitors. An inhibitor of the phosphatidylinositol-specific phospholipase (PI-PLC) U73122 (5 μM), the phosphatidylcholine-specific phospholipase (PC-PLC) D609 (50 μM), the nonreceptor tyrosine kinase PP1(10 μM), the protein kinase C (PKCα) safingol (5 μM) or the protein kinase C (PKCδ) rottlerin (5 μM) was pre-incubated with cells for 1 h. Then, cells were stimulated with TNFα 100 ng/mL for 8 or 24 h before harvesting for RNA or protein extraction. In addition, experiments were conducted for the regulatory role of TNFR on TNFα-stimulated IP 3 R1 expression and PKCα activation. A specific antibody of TNFR1 (10 ng/mL) or TNFR2 (10 ng/mL) was pre-incubated with cells for 1 h prior to TNFα stimulation.
qRT-PCR
Total RNA was extracted from HMCs by the use of the Trizol RNA isolation system in accordance with the instructions of the manufacturer (Invitrogen). The concentration and purity of mRNA were determined by spectrophotometry at 260 and 280 nm. One milligram of RNA was reverse transcribed and used as a template in qRT-PCR on an iCycler (BioRad, Munich, Germany). The PCR reaction mixture at a 25-μL volume contained 12.5 μL of 2× SYBR Green PCR Master Mix, 2 μL RT product, and 0.5 μL sense and anti-sense primer sets. After sequential incubations at 37°C for 5 min and 85°C for 10 min, the amplification protocol consisted of 45 cycles of denaturation at 95°C for 15 s, annealment at 57°C for 15 s and extension at 72°C for 20 s. Each sample was added in triplicate. The primer sequences were as follows:
A standard curve was constructed from serial dilutions of cDNA synthesized from a known quantity of total RNA for IP 3 R1 or β-actin. IP 3 R1 and β-actin values in unknown samples were quantified by the measurement of Ct and by reading the corresponding value of the standard curve. IP 3 R1 expression was then normalized to β-actin expression, and IP 3 R1 expression level in medium-treated control cells was considered to be '1'. All experiments were conducted in triplicates.
Western blot analyses
To detect IP 3 R1 protein, cells were treated and then washed with ice-cold PBS. Afterwards, cells were collected and lysed in RIPA buffer containing (20 mM Tris-HCl, pH 8.0, 150 mM NaCl, 1%Triton X-100, 2 mM EDTA, 1 mM phenylmethylsulphonyl fluoride, 20 mg/mL aprotinin, 10 mg/mL leupeptin, 20 mM β-glycerophate, and 2 mM NaF). The protein concentration was determined with a BCA protein assay reagent kit (Piece Biotech Inc., Rockford, IL, USA). Eighty micrograms were applied to 7% (for IP 3 R1) or 12% (for total PKC, phospho-PKCα) sodium dodecyl sulphate (SDS)-polyacrylamide gels, and electrophoresed. Then, proteins were transferred onto a polyvinylidine difluorid (PVDF) membrane (Millipore). After having been blocked with Tris buffer containing 5% skim milk and probed with polyclonal rabbit anti-human IP 3 R1 antibody (Chemicon, diluted 1:1000) or monoclonal rabbit anti-human β-actin antibodies (Chemicon, diluted 1:1000) or rabbit anti-human PKC, anti-human phospho-PKCα (Cell Signaling Technology, diluted 1:1000) followed respectively by HRP-conjugated secondary antibody. They were then incubated with an enhanced chemiluminescent substrate and exposed to X-OMAT film. The protein expression level was quantified by densitometry.
PKC activity assay
The PKC activity assay was carried out in accordance with the instructions of the PepTag ® Non-Radioactive Protein Kinase C Assay Kit (Promega). The cells were washed once with PBS and lysed in lysis buffer, which contained 20 mM Tris-HCl, 0.5 mM EGTA, 2 mM EDTA, 2 mM dithiothreitol, 1 mM phenylmethanesulphonyl fluoride (PMSF) and 10 mg/mL leupeptin (pH 7.5). Assays were then performed at 30°C in a total volume of 25 µL that included 5 µL PKC reaction 5× buffer, 5 µL PLSRTLSVAAK peptide, 5 µL PKC activator and 1 µL peptide protection solution. Reactions were initiated by the addition of 9 µL of the sample and terminated after 30 min by incubating the reaction mixture at 95°C for 10 min. After the addition of 1 µL of 80% glycerol, each sample was separated by 0.8% agarose gel electrophoresis at 100 V for 15 min.
Transfection plasmids
Two millilitre of culture medium with 3 × 10 5 cells were incubated in a sixwell plate until cells reached 60-80% confluence. The cells were transfected with 4 μg of dominant-negative PKCα construct (pHACE-DN-PKCα K/R), the wild-type PKCα construct (pHACE-WT-PKCα) or the pCDNA 3.0 vector per well. Each of these transfections was performed in the presence of 10 μl/well Lipofectamine 2000 Reagent (Invitrogen Life Technologies) in accordance with the instructions of the manufacturer in opti-MEM. The opti-MEM was then replaced by fresh MCM after a 6-h incubation at 37°C. The confirmation of transfection was performed with the anti-HA antibody and anti-PKCα antibody by western blot after 48 h of incubation. In addition, after a period of 48 h post-transfection, cells were exposed to 100 ng/mL TNFα for 8 or 24 h, and then, the IP 3 R1 mRNA expression or protein expression was analysed by qRT-PCR or western blot.
Data analysis
All the results presented were representative of at least three separate experiments. SPSS version 13.0 software was used to perform the statistical analyses. All quantitative data were given as mean ± SEM, and were analysed using analysis of variance (ANOVA). P-values <0.05 were considered significant.
Results
TNFα-induced IP 3 R1 gene and protein expression (±0.62, P < 0.01) induction at 8 h of TNFα treatment compared with the basal levels. Consistent with the result of qRT-PCR, the levels of IP 3 R1 protein at 24 h post-TNFα exposure were significantly enhanced compared with the basal levels (∼3-fold ±0.317, P < 0.01, Figure 1B ).
Involvement of PKC isoforms and PLC in IP 3 R1 expression induced by TNFα
Firstly, HMCs were treated overnight with 1 μM PMA, which was sufficient to cause an almost complete downregulation of PMA-sensitive PKC isoforms [18] , and the effects were confirmed by using a pan-PKC antibody ( Figure 2B ). Results showed a marked decrease in the level of IP 3 R1 protein expression (P < 0.01; Figure 2A ), thus suggesting the involvement of PMA-sensitive PKC isoforms, that is, cPKC and nPKC in the mechanism of the response. Secondly, as shown in Figure 3A and B, D609 (PC-PLC inhibitor) and safingol (PKCα inhibitor) each suppressed TNFα-induced expression of IP 3 R1 at both the protein and mRNA levels, whereas the effect of TNFα was not affected by U73122, rottlerin or PP1. Inhibitors alone had no significant effect on the basal expression of IP 3 R1. These results point to a positive regulatory role of PC-PLC and PKCα signals in TNFα-induced expression of IP 3 R1 in HMCs.
The effect of DN forms of PKCα on TNFα-induced IP 3 R1 expression
In the group of transient transfection with the pHACE-DN-PKCα or pHACE-WT-PKCα constructs, PKCα protein expression increased, and HA was positive, which confirmed transfection effectiveness ( Figure 4A ). Compared with TNFα stimulation alone, both IP 3 R1 mRNA and protein expression were markedly enhanced in HMCs transfected with the pHACE-WT-PKCα construct, while significantly reduced with the pHACE-DN-PKCα construct ( Figure 4B and C) . Between the group of TNFα stimulation alone and transfection with pCDNA3.0 plasmids, both IP 3 R1 mRNA and protein expression did not differ, suggesting that cell activity could not be influenced by plasmid transfection.
TNFα-activated PKCα and PC-PLC-mediated TNFα-induced PKCα activation in HMCs
TNFα promoted autophosphorylation, and hence the activation, of PKCα with maximal phosphorylation that occurred 8 h post-stimulation measured by western blot analysis using a phospho-specific antibody that recognized the autophosphorylation site (Thr 638), which is required for the full activation of PKCα [19] and non-radioactive PKC assay ( Figure 5B and D) . However, the total PKCα protein expression did not differ between the different groups ( Figure 5A ). In the group that was pre-treated with D609 or safingol, TNFα-induced autophosphorylation of PKCα was markedly attenuated ( Figure 5C and D) , However, U73122 failed to block TNFα-induced PKCα phosphorylation ( Figure 5C ). The specificity of safingol used in this study was also verified by the use of both the non-radioactive PKC assay and immunoblotting methods.
TNFR involvement of PKCα activation and IP 3 R1 expression induced by TNFα
To further investigate the contribution of TNFR1 and TNFR2 in the mediation of TNFα-induced PKCα activation and IP 3 R1 expression, HMCs were pre-treated with anti-TNFR1 or anti-TNFR2 antibodies that blocked their respective receptors [20] . As shown in Figure 6 , the anti-TNFR1 and anti-TNFR2 inhibited TNFα-induced IP 3 R1 protein expression to various degrees, with 40.3% (±0.243; P < 0.01) and 24% (±0.157; P < 0.05) inhibition, respectively ( Figure 6A ). The use of anti-TNFR1 significantly blocked phosphorylated PKCα expression by 42% (±0.107; P < 0.01). However, anti-TNFR2 had no marked effects on PKCα activation (P > 0.05; Figure 6B ).
Discussion
The present study provided the first evidence that TNFα could increase the production of IP 3 R1 by the control of the TNFR1/PC-PLC/PKCα and TNFR2 signalling pathway in HMCs.
Our results were consistent with those of Park et al. [14] in that TNFa increased IP 3 R1 mRNA and protein expression in primary murine neurons. The increased protein expression of IP 3 R1 may be partly due to increased synthesis of the IP 3 R1 as we found an increase in mRNA levels prior to observing an increase in protein levels. Our finding that TNFα increases IP 3 R1 mRNA levels can be explained either by an effect on transcription of IP 3 R1 gene or by reduction of the degradation rate of the mRNA and will require further studies.
The implication of increased IP 3 R1 protein expression is that IP 3 R1 may provide more ligand-binding sites for IP 3 , and promote IP 3 The signal transduction mechanism of TNFα-upregulated IP 3 R1 in HMCs 79
ing to an increase in the contraction ability of HMCs to contraction and a reduction in the renal GFP, which might be an important reason for the occurrence and development of HRS. The molecular mechanisms underlying TNFα-induced IP 3 R1 expression in HMCs have not been explored previously. In this study, we extended our investigation on the mechanisms by which TNFα induced IP 3 R1 expression. It has been reported that TNFα can activate PKCα, PKCε and PKCζ in GMCs [21] [22] [23] , and PKCα and PKCβ in vascular smooth muscle cells and epithelial cells [24, 25] . Moreover, PKC can also translocate to different subcellular compartments such as plasma membrane, caveolae, Golgi apparatus, and perinuclear and nuclear regions depending upon different stimuli including TNFα [26] [27] [28] [29] . Translocation of PKC, especially to the plasma membrane, is thought to be a necessary step for its activation. In addition, TNFα stimulates the activity of the mitogen-activated protein kinase (MAPK) signalling pathway and/or subsequently c-fos induction, in part, via PKC in GMCs [30] [31] [32] . Also, PTK appeared to mediate GMC activation and gene expression stimulated by TNFα [22] . These studies suggest a potential link among gene expression and enhanced activity of PKC and/or PTK in GMCs in response to TNFα.
In cultured HMCs, expressions of PKCα, PKCβ, PKCδ, PKCε and PKCζ have been reported by most investigators [22] . PKCα is one member of the PMA, DAG and Ca 2+ -dependent group. Our data demonstrated that pre- treatment with chronic PMA to delete the endogenous PKC (cPKC and nPKC), PKCα-selective pharmacologic inhibitors safingol, and domain-negative PKCα mutant plasmid transfection all attenuated the TNFα-stimulated IP 3 R1 expression. This indicated that PKCα activation was required for the TNFα-mediated regulation of IP 3 R1 expression. It has been well established that TNFα can trigger the activation of PI-PLC and PC-LC to generate diacylglycerol (DAG), and thereby activate PKC in U937 cells and canine SMCs [33, 34] . In our present investigation, D609 but not U7312 inhibited the TNFα-stimulated activation of PKCα. These results were consistent with the findings that PC-PLC, which is a molecule that produces DAG and phosphorylcholine (Pchol) from PC hydrolysis, is involved in TNFα signalling in various cells [35] [36] [37] .
The activities of TNFα are mediated by two distinct receptors, TNFRp55 (TNFR1) and TNFRp75 (TNFR2). The present data suggested that TNFα-induced PKCα activity was mediated by TNFR1 rather than TNFR2. That is, TNFR1/PC-PLC/PKCα signal pathway enhanced IP 3 R1 expression in HMCs. Consistently, TNFR1 deficiency had no effect on PKCα-mediated induction of KC and MIP-2 [38] , and TNFR1 is required for TNFα-induced activation of PKCα in murine 70Z/3 cells [39] . However, IP 3 R1 expression was markedly reduced in both groups that were pre-treated with the anti-TNFR1 or anti-TNFR2 antibody, which indicates that TNFR2 signalling pathways other than TNFR1 might also be critically related with TNFα-induced IP 3 R1 expression. This result is consistent with the preceding results that PKCα activation inhibition using safingol or D609 was unable to block completely IP 3 R1 expression, suggesting that another pathway may be involved except for TNFR1/PC-PLC/PKCα signalling pathway.
Many of the pro-inflammatory actions of TNFα are mediated by TNFR1 [40, 41] , but in several cases, TNFR1 activation requires the coordinate expression of TNFR2 that can form heterocomplexes with TNFR1 [42, 43] . TNFR2 may also potentiate responses mediated by TNFR1 by the increase of the local concentration of surface-associated TNFα available to TNFR1 [44] . Nevertheless, it is not known whether there is a cause and effect relationship between TNFR1-mediated and TNFR2-mediated IP 3 R1 induction in HMCs.
In conclusion, these observations suggest that the identif ication of TNFR1/PC-PLC/PKCα-dependent and TNFR2-dependent IP 3 R1 genes may also help to elucidate the biological functions of these signal molecules more fully, and the pathway may become an important target for future therapies in TNFα-mediated severe hepatitis. The signal transduction mechanism of TNFα-upregulated IP 3 R1 in HMCs 81
